Searchable abstracts of presentations at key conferences in endocrinology

ea0013oc23 | Novartis Basic Endocrinology Award | SFEBES2007

The corticotropin-releasing factor type 2 receptor selective ligand Urocortin 3 suppresses angiogenesis in vitro and in vivo

Kozak Agnieszka , Pechenick Jowers Tali , Hadoke Patrick , Vale Wylie , Jamieson Pauline

Stimulation of the corticotropin-releasing factor type 2 receptor (CRFR2) by its putative ligands the urocortins may influence cardiovascular function by regulating vascular tone and angiogenesis.We examined whether chronic exposure to the CRFR2-selective ligand Urocortin 3 altered the ability of the receptor to modulate vascular functions by assessing arterial contractility and angiogenesis in response to Urocortin 3 both in control mice and in transgen...